These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 16117818)

  • 21. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes.
    Parisotto R; Gore CJ; Emslie KR; Ashenden MJ; Brugnara C; Howe C; Martin DT; Trout GJ; Hahn AG
    Haematologica; 2000 Jun; 85(6):564-72. PubMed ID: 10870111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the components of the insulin-like growth factors system in GH-deficient adults: effects of twelve-month rhGH treatment.
    Ferrante E; Giavoli C; Porretti S; Vassallo E; Ronchi CL; Lania AG; Beck-Peccoz P; Spada A
    Horm Metab Res; 2006 May; 38(5):352-5. PubMed ID: 16718634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease.
    Fischer F; Schulte H; Mohan S; Tataru MC; Köhler E; Assmann G; von Eckardstein A
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):595-602. PubMed ID: 15521962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
    Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
    Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.
    Iglesias P; Díez JJ; Fernández-Reyes MJ; Méndez J; Bajo MA; Aguilera A; Selgas R
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):741-9. PubMed ID: 15163339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P; Zwimpfer C; Zapf J; Schmid C
    Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
    Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor I and insulin and their abuse in sport.
    Erotokritou-Mulligan I; Holt RI
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):33-43, viii. PubMed ID: 20122448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse.
    Abellan R; Ventura R; Pichini S; Palmi I; Bellver M; Olive R; Pacifici R; Pascual JA; Zuccaro P; Segura J
    Int J Sports Med; 2007 Jan; 28(1):9-15. PubMed ID: 16804802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
    Gonc EN; Kandemir N
    Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
    Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
    J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of physical fitness and endurance exercise on indirect biomarkers of growth hormone and insulin misuse: Immunoassay-based measurement in urine samples.
    Pichini S; Ventura R; Palmi I; di Carlo S; Bacosi A; Langohr K; Abellan R; Pascual JA; Pacifici R; Segura J; Zuccaro P
    J Pharm Biomed Anal; 2010 Dec; 53(4):1003-10. PubMed ID: 20674210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: implications for clinical diagnosis and doping tests.
    Nguyen TV; Nelson AE; Howe CJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
    Clin Chem; 2008 Aug; 54(8):1268-76. PubMed ID: 18567697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects.
    Amato G; Izzo G; La Montagna G; Bellastella A
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):27-32. PubMed ID: 8796135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tracking growth hormone abuse in sport: performance of marker proteins in a controlled setting.
    Bosch J; Such-Sanmartín G; Segura J; Gutiérrez-Gallego R
    Anal Chim Acta; 2012 Oct; 745():118-23. PubMed ID: 22938615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
    Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
    Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection.
    Guha N; Cowan DA; Sönksen PH; Holt RI
    Anal Bioanal Chem; 2013 Dec; 405(30):9669-83. PubMed ID: 23934394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
    Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin, growth hormone and sport.
    Sonksen PH
    J Endocrinol; 2001 Jul; 170(1):13-25. PubMed ID: 11431133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.